# Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Source: https://onco.cc/trials/nct04404283/  
OnCo record `nct04404283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Brentuximab vedotin, Rituximab, Lenalidomide in diffuse large b-cell lymphoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.

## Summary

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT04404283 by Seagen, a wholly owned subsidiary of Pfizer, with 239 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2026-01-23. Interventions recorded: Brentuximab vedotin, Rituximab, Lenalidomide, Placebo. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: ECHELON-3; Brentuximab vedotin with lenalidomide and rituximab in relapsed diffuse large B-cell lymphoma
- Tags: ctgov-ingest
- Registry id: NCT04404283
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 239
- Result: Median overall survival 13.8 against 8.5 months (hazard ratio 0.63, two-sided p = 0.009) and median progression-free survival 4.2 against 2.6 months (hazard ratio 0.53).

## Sources

- ClinicalTrials.gov NCT04404283: https://clinicaltrials.gov/study/NCT04404283

## Connected records

- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- key papers: [Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025/)
- trials: [POLARGO](https://onco.cc/trials/polargo/), [STARGLO](https://onco.cc/trials/starglo/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [CD20](https://onco.cc/targets/cd20/), [CD30](https://onco.cc/targets/cd30/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct04404283.json